The U.S. invests more than $32 billion each year in drug and biomedical research. Why doesn't the federal government then ensure reasonable prices for drugs developed with public funds -- an appropriate return on the public's investment?
Read Whole Story
This December marks the 30th anniversary of the Bayh-Dole Act which in effect gave birth to the idea of tech transfer.
Get top stories and blog posts emailed to me each day. Newsletters may offer personalized content or advertisements. Learn more.